ARK-2 Xenograft Model Service for Endometrial Cancer

The ARK-2 Xenograft Model Service for Endometrial Cancer provides a robust preclinical platform for evaluating therapeutic strategies against aggressive uterine papillary serous carcinoma. Alfa Cytology delivers this specialized service with validated cell lines, standardized protocols, and comprehensive endpoint analysis to advance your endometrial cancer drug development programs.

Overview of ARK-2 Xenograft Model for Endometrial Cancer

The ARK-2 cell line was established from an African American patient diagnosed with advanced-stage uterine papillary serous carcinoma (USPC), a highly aggressive subtype of Type II endometrial cancer. ARK-2 cells exhibit mutant TP53 status with null p53 immunohistochemical staining, misregulated RB regulatory function, and CCNE1 copy number gains, closely recapitulating the molecular landscape of high-grade serous-like endometrial carcinoma. When propagated as xenografts in immunodeficient murine hosts, ARK-2 tumors maintain histological features consistent with serous differentiation and demonstrate robust engraftment, making this model a valuable tool for investigating tumor biology, drug responses, and resistance mechanisms in aggressive endometrial malignancies.

ARK-2 xenografts have been extensively utilized in preclinical studies to evaluate histone deacetylase inhibitors, taxane-based therapies, and targeted agents. The model demonstrates predictable tumor growth kinetics and responds to established cytotoxic agents, providing a reproducible system for pharmacodynamic and efficacy assessments. Figure 1 illustrates the histological characteristics and growth pattern of ARK-2 xenograft tumors in a preclinical setting.

Figure 1. PFKFB3 inhibition shows synergistic activity with chemotherapeutic agents to inhibit cell proliferation in EC cells. (Xiao, Yinan, et al., 2021)

Cell Line Information: ARK-2

ARK-2 is a well-characterized human endometrial cancer cell line derived from uterine papillary serous carcinoma tissue. The following table summarizes the essential characteristics and molecular features of the ARK-2 cell line.

Our Services

Alfa Cytology offers comprehensive ARK-2 Xenograft Model Services tailored to your preclinical research objectives. Our team provides end-to-end support from model establishment and in-life study management to comprehensive endpoint analysis, ensuring reliable and reproducible data for your endometrial cancer therapeutic development pipeline. With validated cell lines and stringent quality control protocols, we deliver consistent tumor growth kinetics and robust pharmacodynamic readouts to accelerate your drug discovery programs.

Workflow of ARK-2 Xenograft Model Construction

The construction of ARK-2 xenograft models follows a standardized, quality-controlled workflow designed to ensure reproducible tumor growth and reliable experimental outcomes. Each step is carefully monitored to maintain cell viability, sterility, and consistent engraftment rates across study cohorts.

1. Cell Line Expansion and Quality Control: ARK-2 cells are expanded from authenticated, low-passage stocks under standardized culture conditions in RPMI 1640 with 10% FBS. Cells are routinely tested for mycoplasma contamination and authenticated by STR profiling prior to inoculation.
2. Cell Harvest and Preparation: Exponentially growing ARK-2 cells are harvested by trypsinization, washed with sterile PBS, and resuspended at the appropriate concentration in serum-free medium or Matrigel mixture. Cell viability is confirmed by trypan blue exclusion, typically requiring >95% viability for optimal engraftment.
3. Animal Preparation and Ethical Review: Immunodeficient mice (nude or NSG strains) are acclimatized under pathogen-free conditions. All procedures are conducted under approved institutional animal care and use committee protocols with strict adherence to ethical guidelines.
4. Tumor Cell Inoculation: ARK-2 cells are injected subcutaneously into the flank region or orthotopically into the uterine horn, depending on study objectives. Standard inoculum ranges from 1 x 10^6 to 5 x 10^6 cells per mouse in a 100-200 microL volume.
5. Tumor Monitoring and Measurements: Tumor development is monitored by palpation and caliper measurements beginning 7-10 days post-inoculation. Tumor volume is calculated using the formula: Volume = (length x width^2) / 2.
6. Treatment Administration: Once tumors reach the target volume (typically 100-200 mm^3), mice are randomized into treatment groups. Test compounds are administered via the designated route (oral gavage, intraperitoneal, or intravenous) according to the study protocol.
7. Endpoint Analysis and Sample Collection: At study termination, tumors are excised, weighed, and processed for downstream analyses including histopathology (H&E), immunohistochemistry, Western blotting, and molecular profiling. Blood and organ samples may be collected for toxicology and pharmacokinetic assessments.

Figure 2: Schematic workflow illustrating the derivation and construction of the ARK-2 Xenograft Model at Alfa Cytology.

Case Study-ARK-2 Xenograft Model Development

In a representative preclinical study, ARK-2 xenografts were established in immunodeficient mice to evaluate the efficacy of a novel therapeutic combination. Tumors were allowed to grow to approximately 150 mm^3 before randomization into treatment cohorts. The study demonstrated significant tumor growth inhibition in the treatment group compared to vehicle controls, with corresponding reductions in tumor weight and volume at endpoint. Pharmacodynamic analysis revealed modulation of target pathways in tumor tissue, supporting the mechanism of action. Histological examination confirmed maintained serous carcinoma morphology throughout the study duration. These data illustrate the utility of the ARK-2 xenograft model for generating robust efficacy and biomarker data in endometrial cancer drug development.

Why Choose Alfa Cytology?

Alfa Cytology combines scientific expertise with operational excellence to deliver high-quality ARK-2 xenograft model services for your preclinical research needs.

• Validated, authenticated ARK-2 cell lines with documented molecular profiles and STR verification.
• Standardized xenograft protocols ensuring consistent tumor growth kinetics and reproducible study outcomes.
• Comprehensive in-life services including tumor monitoring, body weight assessment, and treatment administration.
• Robust endpoint analysis capabilities encompassing histopathology, immunohistochemistry, biomarker analysis, and molecular profiling.
• Dedicated project management with transparent communication and detailed study reporting throughout the engagement.
• Flexible study designs accommodating single-agent, combination, and dose-response evaluations tailored to your program requirements.
• Strict adherence to animal welfare guidelines and regulatory standards in all preclinical operations.

Contact Us

Ready to advance your endometrial cancer therapeutic program with the ARK-2 Xenograft Model? Contact us today to discuss your specific study requirements and discover how Alfa Cytology can support your preclinical research objectives. Reach out to our team to receive a customized proposal and timeline for your ARK-2 xenograft model service.

For research use only. Not intended for any clinical use.